

# NEWS ON THE FLY

*with Spurwing*

Edition: 3 June – 4 June

Welcome to News on the Fly, your essential bi-weekly news update! Here's the top stories in the last few days:

## Phrase of the Day

### “Emergency Use”

In the past week, Gilead Sciences Inc's antiviral drug remdesivir received emergency use approval in India and South Korea in treating COVID-19 patients. Last month, the drug was granted emergency use authorization by the U.S. Food and Drug Administration and has received approval by Japanese health regulators.

## COVID-19: Local news

### [Approved travellers on new Singapore-China 'fast lane' need not serve quarantine but must do COVID-19 swab tests](#)

3 June 2020 | [The Straits Times](#)

Under the new Singapore-China "fast lane" agreement, which will start next Monday (June 8), travellers on both sides will be exempt from rules that require everyone else to serve quarantine periods of up to 14 days.

### [Streets and schools come alive again as Singapore reopens](#)

3 June 2020 | [The Straits Times](#)

Singapore emerged from the circuit breaker period on 2 June to resume activities that had been shut down due to COVID-19. Around 75 per cent of the economy is expected to resume operations in phase one, with about one-third of workers returning to work on-site, up from 17 per cent during the circuit breaker.

### [Drive-through COVID-19 swab test facility launched at One Farrer Hotel](#)

4 June 2020 | [The Straits Times](#)

The first drive-through testing facility has been launched at One Farrer Hotel, which has been repurposed as a temporary hospital facility. People can get their COVID-19 test swabs while seated in their cars or opt to use swab booths nearby.

## COVID-19: Global news

### [Malaria drug touted by Trump fails to prevent COVID-19 in high profile study](#)

4 June 2020 | [Reuters](#)

According to a widely anticipated clinical trial, malaria drug hydroxychloroquine promoted by U.S. President Donald Trump as a treatment for COVID-19 was ineffective in preventing infection in people exposed to the coronavirus.

Contact us for more details:

[hello@spurwingcomms.com](mailto:hello@spurwingcomms.com)

## [WHO restarts drug trial as doubts grow over clinical data](#)

3 June 2020 | [Financial Times](#)

The World Health Organisation will resume trials of the contentious drug hydroxychloroquine after doubts emerged over the validity of a study that led to them being put on hold.

## [Explainer: Can you catch COVID-19 from delivered packages?](#)

2 June 2020 | [Reuters](#)

Experts have debunked fears that COVID-19 can be transmitted through package deliveries, following an outbreak of COVID-19 at a logistics centre in South Korea.

## Global News

## [George Floyd Updates: Protesters Hail Charges Against Police But Seek Broader Change](#)

4 June 2020 | [The New York Times](#)

Minnesota officials have charged all four former police officers for the death of George Floyd, and the officer primarily responsible with second-degree murder. Protesters welcome the news but are calling for systemic change.

## Health

## [Huge dengue outbreak expected this year; more than 9,000 infected and 12 dead so far](#)

3 June 2020 | [The Straits Times](#)

The National Environment Agency (NEA) has warned that Singapore may face the biggest dengue outbreak ever if community action is not taken.

## [Pfizer to invest up to \\$500 million in public drug developers](#)

2 June 2020 | [Reuters](#)

Pfizer will invest up to \$500 million into publicly traded drug developers to fund their treatment candidates and provide access to scientific expertise. The company will make non-controlling investments in biotechs with small- to medium-sized market capitalizations.

## Spurwing Picks of the Week

We've been enjoying useful AI transcription tools like:

- [Otter.ai](#): This app allows for live transcribing, generating rich notes for important voice conversations and meetings.
- [Descript](#): This app allows for recording and editing, even allowing for the removal of filler words. Looking for a tool to record your next podcast episode? This could be it!

Contact us for more details:

[hello@spurwingcomms.com](mailto:hello@spurwingcomms.com)

